Tag Archive for: oncology

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition

/in

Pre-clinical data strongly supports progression of a METTL3 inhibitor in an immuno-oncology setting. STC-15 is the first molecule specifically targeting METTL3 to enter clinical development. 8 August 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and […]

Read more

Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer

/in

Newly appointed CEO has over 20 years’ experience in company building and strategic business development London UK / Cambridge, MA USA, 25 July 2023 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive […]

Read more

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer

/in

Eric Faulkner, currently Sr. Vice President, CMC, appointed as Chief Technical Officer NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced the appointment of Qasim Ahmad, MD, as Chief Medical Officer. Dr. Ahmad joins IO […]

Read more

Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesenas Chief Medical Officer

/in

Dr. Ottesen brings in-depth global clinical development expertise in oncology, including biologics, small molecules, immunotherapies and ADCs Adcendo further builds its world class team to accelerate development of lead ADC asset uPARAP and to expand its first-in-class ADC pipeline Copenhagen, Denmark, June 20, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of […]

Read more

iOnctura To Present Research At Leading Scientific Conferences In June 2023

/in

Geneva, Switzerland and Amsterdam, The Netherlands, 1 June 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023. Read more…

Read more